

SUPPLEMENTARY MATERIAL

Manuscript title

Airway responsiveness to methacholine and incidence of COPD: an international prospective cohort study

Authors

Alessandro Marcon¹, Francesca Locatelli¹, Dirk Keidel^{2,3}, Anna B. Beckmeyer-Borowko^{2,3}, Isa Cerveri⁴, Shyamali C. Dharmage⁵, Elaine Fuertes^{6,7,8}, Judith Garcia-Aymerich^{6,7,8}, Joachim Heinrich⁹, Medea Imboden^{2,3}, Christer Janson¹⁰, Ane Johannessen¹¹, Benedicte Leynaert¹², Silvia Pascual Erquicia¹³, Giancarlo Pesce¹, Emmanuel Schaffner^{2,3}, Cecilie Svanes^{11,14}, Isabel Urrutia Landa¹³, Deborah Jarvis^{15,16}, Nicole Probst-Hensch^{2,3}, Simone Accordini¹

Affiliations

1. Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
2. Department Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
3. University of Basel, Basel, Switzerland
4. Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo Hospital Foundation, University of Pavia, Pavia, Italy
5. Allergy and Lung Health Unit, School of Population and Global Health, University of Melbourne, Melbourne, Australia
6. Institute for Global Health (ISGlobal), Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
7. Universitat Pompeu Fabra (UPF), Barcelona, Spain
8. CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
9. Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Ludwig Maximilians University, Munich, Comprehensive Pneumology Centre Munich, German Centre for Lung Research, Muenchen, Germany
10. Department of Medical Sciences: Respiratory, Allergy and Sleep research, Uppsala University, Uppsala, Sweden
11. Centre for International Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
12. Inserm UMR 1152. Pathophysiology and Epidemiology of Respiratory Diseases; University Paris Diderot Paris 7, UMR 1152, F-75890, Paris, France
13. Respiratory Department, Galdakao Hospital, OSI Barrualde-Galdakao, Biscay, Spain
14. Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway
15. Population Health & Occupational Disease, National Heart and Lung Institute, Imperial College London, London, UK
16. MRC-PHE Centre for Environment and Health, Imperial College London, London, UK.

METHODS

Definition of COPD based on the GOLD clinical criteria

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for the diagnosis, management and prevention of COPD identify a set of key indicators for considering a diagnosis of COPD, which includes a history of symptoms, a history of exposure to air pollution, a family history of COPD and early life risk factors (1). According to the guidelines an individual older than 40 years of age with any of key indicators should be diagnosed as COPD if spirometry confirms the presence of persistent airflow limitation.

For sensitivity analysis we repeated the main analysis using a definition of COPD based on the GOLD clinical criteria (labelled COPD_{clinical}). Incidence of COPD_{clinical} was defined as a combination of a post-BD FEV₁/FVC <lower limit of normal (LLN) (2) at the 3rd examination with at least one of:

- a) **history of symptoms:** either shortness of breath after strenuous activity in the last 12 months; or dyspnoea (trouble with breathing); or chronic cough, or chronic sputum production (usual cough or phlegm on most days for as long as 3 months during winter);
- b) **history of air pollution exposures:** either having smoked ≥ 10 pack-years (3,4); or reporting occupational exposures to vapours, dust, gas or fumes over lifetime;
- c) **family history of COPD and/or childhood risk factors:** either reporting that biological parents ever had chronic bronchitis, emphysema, or COPD (the latter was only available in ECRHS); or reporting a serious respiratory infection within 5 years of age.

As in the main analysis, we excluded subjects with a pre-BD FEV₁/FVC <LLN (2) at the 2nd examination.

Alternative indicator of airway responsiveness in ECRHS

The method originally used to calculate the methacholine dose-response slope was different between ECRHS and SAPALDIA.

In ECRHS the “least-squares” slope was developed by Chinn et al to account for systematic differences in the dose delivered by different Mefar nebulizers (5). It was calculated by regressing percentage fall in FEV₁ on log₁₀ dose using all FEV₁ measurements (except post-saline FEV₁) and then reciprocally transformed ($100 / [DRS + 10]$) (5). For the sake of consistency across the centres, only the doses of methacholine up to 1 mg were considered to derive the slope.

In SAPALDIA, the “two-point” method by O’Connor et al. was used (6,7). To improve consistency between studies (as described in the manuscript), we calculated the two-point slope also for ECRHS and conducted a pooled analysis. Unlike the least-squares slope, the two-point slope does not require mathematical transformations and is therefore easier to interpret.

For sensitivity analysis we repeated the main analysis using the transformed least-squares slope as an alternative indicator of responsiveness. This analysis was carried out only for the ECRHS cohort and, unlike the main analysis, it included all ECRHS centres (regardless of the maximum cumulative dose of methacholine reached). The results of this analysis are reported in Table E4.

TABLES

Table E1: Brands of the spirometers used by study and centre.*

Study	Country	Centre	1 st examination	2 nd examination	3 rd examination
ECRHS	Belgium	Antwerp South	SensorMedics (D)	Jaeger Masterscope	NDD Easyone
		Antwerp City	SensorMedics (D)	Jaeger Masterscope	NDD Easyone
	Germany	Erfurt	Jaeger Masterscope	Jaeger Masterscope	NDD Easyone
	Spain	Galdakao	Biomedin	Biomedin	NDD Easyone
	France	Bordeaux	Vitalograph	Vitalograph	NDD Easyone
		Grenoble	Biomedin	Biomedin	NDD Easyone
		Montpellier	Biomedin	Biomedin	NDD Easyone
		Paris	Biomedin	Biomedin	NDD Easyone
	Italy	Pavia	Biomedin	Biomedin	NDD Easyone
		Turin**	Biomedin	Biomedin	Biomedin
		Verona**	Biomedin	Biomedin	Biomedin
	Iceland	Reykjavik	SensorMedics (D)	SensorMedics (D)	NDD Easyone
	Norway	Bergen	SensorMedics (D)	SensorMedics (D)	NDD Easyone
	Sweden	Göteborg	SensorMedics (D)	SensorMedics (D)	NDD Easyone
		Umeå	SensorMedics (D)	SensorMedics (D)	NDD Easyone
		Uppsala	SensorMedics (D)	SensorMedics (D)	NDD Easyone
Australia	Melbourne	Fleish	SensorMedics (D)	NDD Easyone	
SAPALDIA	Switzerland	Basel***	SensorMedics (H)	SensorMedics (H)	NDD Easyone
		Wald	SensorMedics (H)	SensorMedics (H)	NDD Easyone
		Davos	SensorMedics (H)	SensorMedics (H)	NDD Easyone
		Lugano	SensorMedics (H)	SensorMedics (H)	NDD Easyone
		Montana	SensorMedics (H)	SensorMedics (H)	NDD Easyone
		Payerne	SensorMedics (H)	SensorMedics (H)	NDD Easyone
		Aarau	SensorMedics (H)	SensorMedics (H)	NDD Easyone
Geneva	SensorMedics (H)	SensorMedics (H)	NDD Easyone		

* SensorMedics (D) is a volume-displacement spirometer and SensorMedics (H) is a heated-wire spirometer

** Turin and Verona were not included in the analysis of COPD incidence because post-BD spirometry was not carried out

*** Subjects from Basel aged 20–44 in 1991 participating in ECRHS (n=854), who were also part of the larger sample recruited for SAPALDIA (n=1111, age 18–60), are considered as part of SAPALDIA throughout the analyses

Table E2. Multiple regression coefficients with 95% CIs for the association between increasing airway responsiveness and decline in FEV₁.*

	Slope group, by quintiles (% × μmol ⁻¹)	ΔFEV ₁ (mL/year)	P _{int} ***	ΔFEV ₁ % (%/year)	P _{int} ***
Overall (n=4200)	<0.44	0	-	0	-
	0.44–0.73	-0.1 (-2.5, 2.4)		0.01 (-0.06, 0.08)	
	0.74–1.12	-1.5 (-4.0, 1.0)		-0.01 (-0.08, 0.06)	
	1.13–1.84	0.4 (-2.1, 2.9)		0.08 (0.01, 0.15)	
	≥1.84	-1.0 (-3.6, 1.6)		0.08 (0.01, 0.16)	
Non-smoker (n=1880)	<0.44	0	0.53	0	0.29
	0.44–0.73	1.7 (-2.0, 5.3)		0.07 (-0.04, 0.17)	
	0.74–1.12	-1.1 (-4.8, 2.6)		-0.01 (-0.11, 0.10)	
	1.13–1.84	-0.3 (-4.0, 3.5)		0.05 (-0.06, 0.16)	
	≥1.84	-1.5 (-5.3, 2.3)		0.05 (-0.06, 0.16)	
Smoker** (n=2187)	<0.44	0	0.56	0	0.55
	0.44–0.73	-1.0 (-4.5, 2.6)		-0.01 (-0.11, 0.09)	
	0.74–1.12	-1.5 (-5.0, 2.2)		-0.00 (-0.10, 0.10)	
	1.13–1.84	1.7 (-1.8, 5.3)		0.12 (0.02, 0.22)	
	≥1.84	0.7 (-3.0, 4.4)		0.15 (0.04, 0.25)	
No asthma (n=3223)	<0.44	0	0.56	0	0.55
	0.44–0.73	0.0 (-2.7, 2.7)		0.02 (-0.05, 0.10)	
	0.74–1.12	-0.9 (-3.6, 1.8)		0.01 (-0.07, 0.08)	
	1.13–1.84	1.2 (-1.6, 3.9)		0.10 (0.02, 0.18)	
	≥1.84	-0.7 (-3.7, 2.3)		0.08 (-0.00, 0.16)	
Asthma (n=977)	<0.44	0	0.56	0	0.55
	0.44–0.73	0.2 (-6.3, 6.6)		-0.02 (-0.21, 0.17)	
	0.74–1.12	-3.4 (-9.6, 2.7)		-0.07 (-0.25, 0.11)	
	1.13–1.84	-2.9 (-8.9, 3.1)		-0.03 (-0.21, 0.15)	
	≥1.84	-1.7(-7.1, 3.6)		-0.03 (-0.09, 0.23)	

* regression coefficients represent the mean difference between groups of subjects with increasing airway responsiveness and the reference category. Adjusted for study, sex, education, FEV₁ predicted, age, BMI, BMI², ΔBMI, history of asthma/asthma-like symptoms (when applicable), history of active smoking (when applicable), second-hand smoking, and occupational exposures to vapours, gas, dusts or fumes.

** also adjusted for lifetime pack-years (data not available for 133 subjects)

*** p-values for the interactions between slope group and stratification variable

Table E3: Incidence rate ratios (IRRs) with 95% CIs for the association between increasing airway responsiveness and the development of COPD_{LLN}, stratified by study.*

	ECRHS	SAPALDIA	
Slope group, by quintiles (% × μmol ⁻¹)	IRR (95% CIs)	IRR (95% CIs)	p _{int} **
No. of subjects	1638	2099	
<0.44	1.0	1.0	
0.44–0.73	1.80 (0.32, 10.16)	1.65 (0.25, 10.92)	
0.74–1.12	2.90 (0.58, 14.58)	4.02 (1.15, 18.05)	0.27
1.13–1.84	3.96 (1.06, 14.80)	9.39 (1.47, 34.78)	
≥1.84	7.49 (2.27, 24.69)	9.95 (2.45, 40.41)	

* Adjusted for sex, education, FEV₁ predicted, age, BMI, history of asthma/asthma-like symptoms, history of active smoking, second-hand smoking, and occupational exposures to vapours, gas, dusts or fumes

** p-value for the interaction between slope group and study

Table E4: Incidence rate ratios (IRRs) with 95% CIs for the association between increasing airway responsiveness and the development of COPD_{LLN}: sensitivity analyses on the airway responsiveness indicator.*

Mean two-point slope between the 1 st and 2 nd examinations (% × μmol ⁻¹)		Transformed least-squares slope at the 1 st examination (log ₁₀ (mg) × % ⁻¹)**	
Group, by quartiles	IRR (95% CIs)	Group, by quintiles	IRR (95% CIs)
No. of subjects	3041		2199
<0.56	1	≥9.3	1
0.56–0.90	5.01 (0.95, 26.34)	8.4–9.2	1.33 (0.43, 4.18)
0.91–1.49	10.17 (2.96, 34.88)	7.6–8.3	2.80 (1.00, 7.89)
≥1.50	16.70 (4.14, 67.42)	6.2–7.5	3.00 (1.16, 7.77)
		<6.2	4.10 (1.56, 10.80)

* adjusted for study (only analysis on the two-point slope), sex, education, FEV₁ predicted, age, BMI, history of asthma/asthma-like symptoms, history of active smoking, second-hand smoking, and occupational exposures to vapours, gas, dusts or fumes

** decreasing values correspond to increasing airway responsiveness; analysis on the ECRHS cohort alone

Table E5: Incidence rate ratios (IRRs) with 95% CIs for the association between increasing airway responsiveness and the development of COPD_{LLN}: sensitivity analysis adjusted for use of inhaled/oral medication for asthma at the 1st examination.

Slope group, by quintiles (% × μmol ⁻¹)	IRR (95% CIs)*
No. of subjects	851
<0.44	1
0.44–0.73	1.25 (0.19, 8.34)
0.74–1.12	2.02 (0.50, 8.08)
1.13–1.84	5.09 (1.43, 18.07)
≥1.84	3.47 (1.14, 10.53)

* analysis on subjects with asthma/asthma-like symptoms, adjusted for study, sex, education, FEV₁ predicted, age, BMI, history of active smoking, second-hand smoking, occupational exposures to vapours, gas, dusts or fumes, and current use of inhalers, aerosols or tablets for asthma at the 1st examination

REFERENCES

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD (updated 2017). Available at: <http://goldcopd.org/>. Accessed November 2, 2017.
2. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J*. 2012;40:1324–43.
3. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI; ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. *N Engl J Med* 2011;365:1184–1192.
4. de Marco R, Marcon A, Rossi A, Antó JM, Cerveri I, Gislason T, Heinrich J, Janson C, Jarvis D, Kuenzli N, Leynaert B, Probst-Hensch N, Svanes C, Wjst M, Burney P. Asthma, COPD and overlap syndrome: a longitudinal study in young European adults. *Eur Respir J*. 2015;46:671-9.
5. Chinn S, Burney P, Jarvis D, Luczynska C. Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECRHS). *Eur Respir J* 1997;10:2495–501.
6. O'Connor G, Sparrow D, Taylor D, Segal M, Weiss S. Analysis of dose-response curves to methacholine. An approach suitable for population studies. *Am Rev Respir Dis*. 1987;136:1412–7.
7. Schwartz J, Schindler C, Zemp E, Perruchoud AP, Zellweger JP, Wüthrich B, Leuenberger P, Ackermann-Lieblich U. Predictors of methacholine responsiveness in a general population. *Chest*. 2002;122:812–20.

ACKNOWLEDGEMENTS

ECRHS STUDY

ECRHS I

Co-ordinating Centre (London): P Burney, S Chinn, C Luczynska†, D Jarvis, E Lai.

Project Management Group: P Burney (Project leader-UK), S Chinn (UK), C Luczynska † (UK), D Jarvis (UK), P Vermeire† (Antwerp), H Kesteloot (Leuven), J Bousquet (Montpellier), D Nowak (Hamburg), J Prichard † (Dublin), R de Marco† (Verona), B Rijcken (Groningen), JM Anto (Barcelona), J Alves (Oporto), G Boman (Uppsala), N Nielsen (Copenhagen), P Paoletti (Pisa).

Financial support: The following grants helped to fund the local studies. **Australia:** Asthma Foundation of Victoria, Allen and Hanbury's, **Belgium:** Belgian Science Policy Office, National Fund for Scientific Research, **Estonia:** Estonian Science Foundation, grant no 1088, **France:** Ministère de la Santé, Glaxo France, Insitut Pneumologique d'Aquitaine, Contrat de Plan Etat-Région Languedoc-Rousillon, CNMATS, CNMRT (90MR/10, 91AF/6), Ministre delegué de la santé, RNSP, France; GSF, **Germany:** Bundesminister für Forschung und Technologie, **Italy:** Ministero dell'Università e della Ricerca Scientifica e Tecnologica, CNR, Regione Veneto grant RSF n. 381/05.93, **Norway:** Norwegian Research Council project no. 101422/310, **Spain:** Fondo de Investigación Sanitaria (#91/0016-060-05/E, 92/0319 and #93/0393), Hospital General de Albacete, Hospital General Juan Ramón Jiménez, Dirección Regional de Salud Pública (Consejería de Sanidad del Principado de Asturias), CIRIT (1997 SGR 00079) and Servicio Andaluz de Salud, **Sweden:** The Swedish Medical Research Council, the Swedish Heart Lung Foundation, the Swedish Association against Asthma and Allergy, **Switzerland:** Swiss national Science Foundation grant 4026-28099, **UK:** National Asthma Campaign, British Lung Foundation, Department of Health, South Thames Regional Health Authority.

Coordination: The co-ordination of this work was supported by the European Commission and the authors and participants are grateful to the late C. Baya and M. Hallen for their help during the study and K. Vuylsteek and the members of the COMAC for their support.

ECRHS II

Steering Committee: U. Ackermann-Lieblich (University of Basel, Switzerland); N. Kuenzli (University of Basel, and University of Southern California, Los Angeles, USA); J.M. Antó and J. Sunyer (Institut Municipal d' Investigació Mèdica (IMIM-IMAS), Universitat Pompeu Fabra (UPF), Spain); P. Burney (project leader), S Chinn, D. Jarvis, J. Knox and C. Luczynska (King's College London, UK); I. Cerveri (University of Pavia, Italy); R. de Marco† (University of Verona, Italy); T. Gislason (Iceland University Hospital, Iceland); J. Heinrich and M. Wjst (GSF–Institute of Epidemiology, Germany); C. Janson (Uppsala University, Sweden); B. Leynaert and F. Neukirch (Institut National de la Sante' et de la Recherche Meidicale (INSERM),France); J. Schouten (University of Groningen, The Netherlands); C. Svanes (University of Bergen, Norway); P. Vermeire† (University of Antwerp, Belgium).

Principal Investigators and senior scientific teams: **Australia:** (M. Abramson, E.H Walters, J. Raven); **Belgium:** South Antwerp and Antwerp City (P. Vermeire, J. Weyler, M. van Sprundel, V. Nelen);

Estonia: Tartu (R. Jõgi, A. Soon); **France: Paris** (F. Neukirch, B. Leynaert, R. Liard, M. Zureik), **Grenoble** (I. Pin, J. Ferran-Quentin), **Bordeaux** (A. Taytard, C. Raheison), **Montpellier** (J. Bousquet, P. J. Bousquet); **Germany: Erfurt** (J. Heinrich, M. Wjst, C. Frye, I. Meyer); **Iceland: Reykjavik** (T. Gislason, E. Bjornsson, D. Gislason, K.B. Jörundsdóttir); **Italy: Turin** (R. Bono, M. Bugiani, P. Piccioni, E. Caria, A. Carosso, E. Migliore, G. Castiglioni), **Verona** (R. de Marco†, G. Verlato, E. Zanolin, S. Accordini, A. Poli, V. Lo Cascio, M. Ferrari, I. Cazzoletti), **Pavia** (A. Marinoni, S. Villani, M. Ponzio, F. Frigerio, M. Comelli, M. Grassi, I. Cerveri, A. Corsico); **Norway: Bergen** (A. Gulsvik, E. Omenaas, C. Svanes, B. Laerum); **Spain: Albacete** (J. Martinez-Moratalla Rovira, E. Almar, M. Arévalo, C. Boix, G. González, J.M. Ignacio García, J. Solera, J. Damián), **Galdakao** (N. Muñozguren, J. Ramos, I. Urrutia, U. Aguirre), **Barcelona** (J. M. Antó, J. Sunyer, M. Kogevinas, J. P. Zock, X. Basagaña, A. Jaen, F. Burgos, C. Acosta), **Huelva** (J. Maldonado, A. Pereira, J.L. Sanchez), **Oviedo** (F. Payo, I. Huerta, A. de la Vega, L. Palenciano, J. Azofra, A. Cañada); **Sweden: Göteborg** (K. Toren, L. Lillienberg, A. C. Olin, B. Balder, A. Pfeifer-Nilsson, R. Sundberg), **Umea** (E. Norrman, M. Soderberg, K.A. Franklin, B. Lundback, B. Forsberg, L. Nystrom), **Uppsala** (C. Janson, G. Boman, D. Norback, G. Wieslander, M. Gunnbjornsdottir); **Switzerland: Basel** (N. Küenzli, B. Dibbert, M. Hazenkamp, M. Brutsche, U. Ackermann-Liebrich); **United Kingdom: Ipswich** (D. Jarvis, R. Hall, D. Seaton), **Norwich** (D. Jarvis, B. Harrison).

Financial Support: **Australia:** National Health and Medical Research Council; **Belgium:** Antwerp: Fund for Scientific Research (grant code, G.0402.00), University of Antwerp, Flemish Health Ministry; **Estonia: Tartu** Estonian Science Foundation grant no 4350; **France: (All)** Programme Hospitalier de Recherche Clinique—Direction de la Recherche Clinique (DRC) de Grenoble 2000 number 2610, Ministry of Health, Ministère de l'Emploi et de la Solidarité, Direction Générale de la Santé, Centre Hospitalier Universitaire (CHU) de Grenoble, **Bordeaux:** Institut Pneumologique d'Aquitaine, **Grenoble:** Comité des Maladies Respiratoires de l'Isère, **Montpellier:** Aventis (France), Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon, **Paris:** Union Chimique Belge-Pharma (France), Aventis (France), Glaxo France; **Germany: Erfurt** GSF—National Research Centre for Environment and Health, Deutsche Forschungsgemeinschaft (grant code, FR1526/1-1), **Hamburg:** GSF—National Research Centre for Environment and Health, Deutsche Forschungsgemeinschaft (grant code, MA 711/4-1); **Iceland: Reykjavik,** Icelandic Research Council, Icelandic University Hospital Fund; **Italy: Pavia** GlaxoSmithKline Italy, Italian Ministry of University and Scientific and Technological Research (MURST), Local University Funding for Research 1998 and 1999, **Turin:** Azienda Sanitaria Locale 4 Regione Piemonte (Italy), Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico—Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte, **Verona:** Ministero dell'Università e della Ricerca Scientifica (MURST), Glaxo Wellcome spa; **Norway: Bergen:** Norwegian Research Council, Norwegian Asthma and Allergy Association, Glaxo Wellcome AS, Norway Research Fund; **Spain:** Fondo de Investigación Sanitarias (grant codes, 97/0035-01, 99/0034-01 and 99/0034-02), Hospital Universitario de Albacete, Consejería de Sanidad, **Barcelona:** Sociedad Española de Neumología y Cirugía Torácica, Public Health Service (grant code, R01 HL62633-01), Fondo de Investigaciones Sanitarias (grant codes, 97/0035-01, 99/0034-01, and 99/0034-02), Consell Interdepartamental de Recerca i Innovació Tecnològica (grant code, 1999SGR 00241) Instituto de Salud Carlos III; Red de Centros de Epidemiología y Salud Pública, C03/09, Red de Bases moleculares y fisiológicas de las Enfermedades Respiratorias, C03/011 and Red de Grupos Infancia y Medio Ambiente G03/176, **Huelva:** Fondo de Investigaciones Sanitarias (grant codes, 97/0035-01, 99/0034-01, and 99/0034-02), **Galdakao:** Basque Health Department, **Oviedo:** Fondo de Investigaciones Sanitarias (97/0035-02, 97/0035, 99/0034-01, 99/0034-02, 99/0034-04, 99/0034-06, 99/350, 99/0034-07), European Commission (EU-PEAL PL01237), Generalitat de Catalunya (CIRIT 1999 SGR 00214), Hospital Universitario de Albacete, Sociedad Española de Neumología y Cirugía Torácica (SEPAR R01 HL62633-01) Red de Centros de Epidemiología y Salud Pública (C03/09), Red de Bases moleculares y fisiológicas de las Enfermedades Respiratorias (C03/011) and Red de Grupos Infancia y Medio Ambiente

(G03/176);97/0035-01, 99/0034-01, and99/0034-02); **Sweden: Göteborg, Umea, Uppsala:** Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences and Allergy Research, Swedish Asthma and Allergy Foundation, Swedish Cancer and Allergy Foundation, Swedish Council for Working Life and Social Research (FAS); **Switzerland: Basel** Swiss National Science Foundation, Swiss Federal Office for Education and Science, Swiss National Accident Insurance Fund; **UK: Ipswich and Norwich:** Asthma UK (formerly known as National Asthma Campaign).

Cordination: The coordination of this work was supported by the European Commission, as part of their Quality of Life programme, (Grant code: QLK4-CT-1999-01237).

ECRHS III

Principal Investigators and senior scientific teams: **Australia: Melbourne** (M.Abramson, G. Benke, S. Dharmage, B. Thompson, S. Kaushik, M Matheson. **Belgium: South Antwerp & Antwerp City** (J. Weyler, H.Bentouhami, V. Nelen). **Estonia:** Tartu (R. Jõgi, H.Orru). **France: Bordeaux** (C. Raheison, P.O Girodet) **Grenoble** (I. Pin, V. Siroux, J.Ferran, J.L Cracowski) **Montpellier** (P. Demoly,A.Bourdin, I. Vachier) **Paris** (B. Leynaert, D. Soussan, D. Courbon, C. Neukirch, L. Alavoine, X. Duval, I. Poirier). **Germany: Erfurt** (J .Heinrich, E. Becker, G. Woelke, O. Manuwald) **Hamburg** (H. Magnussen, D. Nowak, A-M Kirsten). **Iceland: Reykjavik** (T. Gislason, B. Benediktsdottir, D. Gislason, E.S Arnardottir, M. Clausen, G. Gudmundsson, L. Gudmundsdottir, H. Palsdottir, K. Olafsdottir, S. Sigmundsdottir, K. Bara-Jörundsdottir). **Italy: Pavia** (I .Cerveri, A.Corsico, A. Grosso, F. Albicini, E. Gini, E.M Di Vincenzo, V. Ronzoni, S. Villani, F. Campanella, M. Gnesi, F. Manzoni, L. Rossi, O. Ferraro) **Turin:** (M. Bugiani, R. Bono, P. Piccioni, R. Tassinari, V. Bellisario, G. Trucco) **Verona:** (R de Marco†, S. Accordini, L. Calciano, L. Cazzoletti, M. Ferrari, A.M Fratta Pasini, F. Locatelli, P. Marchetti, A. Marcon, E. Montoli, G. Nguyen, M. Olivieri, C. Papadopoulou, C.Posenato, G. Pesce, P. Vallerio, G. Verlato, E. Zanolin). **Norway:** (C. Svanes, E. Omenaas, A. Johannessen, T. Skorge, F. Gomez Real). **Spain: Albacete** (J. Martinez-Moratalla Rovira, E. Almar, A. Mateos, S. García, A. Núñez, P.López, R. Sánchez, E Mancebo), **Barcelona:** (J-M. Antó, J.P Zock, J Garcia-Aymerich, M Kogevinas, X. Basagaña, A.E. Carsin, F. Burgos, C. Sanjuas, S Guerra, B. Jacquemin, P.Davdand, **Galdakao:** N. Muñozguren, I. Urrutia, U. Aguirre, S. Pascual), **Huelva:**(J Antonio Maldonado, A. Pereira, J. Luis Sánchez, L. Palacios, **Oviedo:** (F. Payo, I. Huerta, N. Sánchez, M. Fernández, B. Robles). **Sweden: Göteborg** (K. Torén, M. Holm, J-L Kim, A-C. Olin, A. Dahlman-Höglund), **Umea** (B. Forsberg, L. Braback, L Modig, B Järvalho, H Bertilsson, K.A Franklin, C Wahlgreen), **Uppsala:** (B Andersson, D Norback, U Spetz Nystrom, G Wieslander, G.M Bodinaa Lund, K Nisser); **Switzerland: Basel** (N.M. Probst-Hensch, N. Künzli, D. Stolz, C. Schindler, T. Rochat, J.M. Gaspoz, E. Zemp Stutz, M.Adam, C. Autenrieth, I. Curjuric, J. Dratva, A. Di Pasquale, R. Ducret-Stich, E. Fischer, L. Grize, A. Hensel, D. Keidel, A. Kumar, M. Imboden, N. Maire, A. Mehta, H. Phuleria, M. Ragettli, M. Ritter, E. Schaffner, G.A Thun, A. Ineichen, T. Schikowski, M. Tarantino, M. Tsai. **UK: London** (P. Burney, D. Jarvis, S. Kapur, R. Newson, J. Potts), **Ipswich:** (N. Innes), **Norwich:** (A. Wilson).

Financial Support: **Australia:** National Health & Medical Research Council. **Belgium: Antwerp South, Antwerp City:** Research Foundation Flanders (FWO), grant code G.0.410.08.N.10 (both sites). **Estonia: Tartu-** SF0180060s09 from the Estonian Ministry of Education. **France: (All)** Ministère de la Santé. Programme Hospitalier de Recherche Clinique (PHRC) national 2010. **Bordeaux:** INSERM U897 Université Bordeaux segalen, **Grenoble:** Comite Scientifique AGIRadom 2011. **Paris:** Agence Nationale de la Santé, Région Ile de France, domaine d'intérêt majeur (DIM). **Germany: Erfurt:** German Research Foundation HE 3294/10-1 **Hamburg:** German Research Foundation MA 711/6-1, NO 262/7-1. **Iceland:** Reykjavik, The Landspítali University Hospital Research Fund, University of Iceland Research Fund,

ResMed Foundation, California, USA, Orkuveita Reykjavíkur (Geothermal plant), Vegagerðin (The Icelandic Road Administration (ICERA)). **Italy:** All Italian centres were funded by the Italian Ministry of Health, Chiesi Farmaceutici SpA, in addition **Verona** was funded by Cariverona foundation, Education Ministry (MIUR). **Norway:** Norwegian Research council grant no 214123, Western Norway Regional Health Authorities grant no 911631, Bergen Medical Research Foundation. **Spain:** Fondo de Investigación Sanitaria (PS09/02457, PS09/00716 09/01511) PS09/02185 PS09/03190), Servicio Andaluz de Salud , Sociedad Española de Neumología y Cirugía Torácica (SEPAR 1001/2010). Fondo de Investigación Sanitaria (PS09/02457), **Barcelona:** Fondo de Investigación Sanitaria (FIS PS09/00716), **Galdakao:** Fondo de Investigación Sanitaria (FIS 09/01511) **Huelva:** Fondo de Investigación Sanitaria (FIS PS09/02185) and Servicio Andaluz de Salud **Oviedo:** Fondo de Investigación Sanitaria (FIS PS09/03190). **Sweden:** All centres were funded by The Swedish Heart and Lung Foundation, The Swedish Asthma and Allergy Association, The Swedish Association against Lung and Heart Disease, Swedish Research Council for health, working life and welfare (FORTE) **Göteborg** : Also received further funding from the Swedish Council for Working life and Social Research. Umea also received funding from Vasterbotten Country Council ALF grant. **Switzerland:** The Swiss National Science Foundation (grants no 33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099) The Federal office for forest, environment and landscape, The Federal Office of Public Health, The Federal Office of Roads and Transport, the canton's government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais and Zürich, the Swiss Lung League, the canton's Lung League of Basel Stadt/ Basel, Landschaft, Geneva, Ticino, Valais and Zurich, SUVA, Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics GmbH, Abbott Diagnostics, European Commission 018996 (GABRIEL), Wellcome Trust WT 084703MA. **UK:** Medical Research Council (Grant Number 92091). Support also provided by the National Institute for Health Research through the Primary Care Research Network.

Coordination: The coordination was funded through the Medical Research Council (Grant Number 92091).

† deceased

SAPALDIA STUDY

CURRENT SAPALDIA TEAM

Study directorate: NM Probst-Hensch (PI; e/g); T Rochat (p), C Schindler (s), N Künzli (e/exp), JM Gaspoz (c)

Scientific team: JC Barthélémy (c), W Berger (g), R Bettschart (p), A Bircher (a), C Brombach (n), PO Bridevaux (p), L Burdet (p), Felber Dietrich D (e), M Frey (p), U Frey (pd), MW Gerbase (p), D Gold (e), E de Groot (c), W Karrer (p), F Kronenberg (g), B Martin (pa), A Mehta (e), D Miedinger (o), M Pons (p), F Roche (c), T Rothe (p), P Schmid-Grendelmeyer (a), D Stolz (p), A Schmidt-Trucksäss (pa), J Schwartz (e), A Turk (p), A von Eckardstein (cc), E Zemp Stutz (e).

Scientific team at coordinating centers: M Adam (e), I Aguilera (exp), A Beckmeyer-Borowko (e), S Brunner (s), D Carballo (c), S Caviezel (pa), I Curjuric (e), A Di Pascale (s), J Dratva (e), R Ducret (s), E Dupuis Lozeron (s), M Eeftens (exp), I Eze (e), E Fischer (g), M Foraster (e), M Germond (s), L Grize (s), S Hansen (e), A Hensel (s), M Imboden (g), A Ineichen (exp), A Jeong (g), D Keidel (s), A Kumar (g), N Maire (s), A Mehta (e), R Meier (exp), E Schaffner (s), T Schikowski (e), M Tsai (exp)

(a) allergology, (c) cardiology, (cc) clinical chemistry, (e) epidemiology, (exp) exposure, (g) genetic and molecular biology, (m) meteorology, (n) nutrition, (o) occupational health, (p) pneumology, (pa) physical activity, (pd) pediatrics, (s) statistics

Research support: The Swiss National Science Foundation (grants no 33CS30-148470/1&2, 33CSCO-134276/1, 33CSCO-108796, , 324730_135673, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099, PMPDP3_129021/1, PMPDP3_141671/1), the Federal Office for the Environment, the Federal Office of Public Health, the Federal Office of Roads and Transport, the canton's government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Zürich, the Swiss Lung League, the canton's Lung League of Basel Stadt/ Basel Landschaft, Geneva, Ticino, Valais, Graubünden and Zurich, Stiftung ehemals Bündner Heilstätten, SUVA, Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics GmbH, Abbott Diagnostics, European Commission 018996 (GABRIEL), Wellcome Trust WT 084703MA, Exposomics EC FP7 grant (Grant agreement No: 308610).

Acknowledgements: The study could not have been done without the help of the study participants, technical and administrative support and the medical teams and field workers at the local study sites. Local fieldworkers : Aarau: S Brun, G Giger, M Sperisen, M Stahel, Basel: C Bürli, C Dahler, N Oertli, I Harreh, F Karrer, G Novicic, N Wyttenbacher, Davos: A Saner, P Senn, R Winzeler, Geneva: F Bonfils, B Blicharz, C Landolt, J Rochat, Lugano: S Boccia, E Gehrig, MT Mandia, G Solari, B Viscardi, Montana: AP Bieri, C Darioly, M Maire, Payerne: F Ding, P Danieli A Vonnez, Wald: D Bodmer, E Hochstrasser, R Kunz, C Meier, J Rakic, U Schafroth, A Walder.

Administrative staff: N Bauer Ott, C Gabriel, R Gutknecht.